After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Kyle LaHucik

Biotech Correspondent

Brain health biotech Neumora has stopped two of its Phase 3 trials in major depressive disorder to make adjustments after the first late-stage study unexpectedly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Omada Health is going public on Friday at a $1.1B valuation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another